Table 3.
Relative expression of selected genes commonly regulated in Post- vs Pre-CPB right atrial samples from ToF and ASD patients
| Function | Gene symbol | Gene description | Fold changea | |
|---|---|---|---|---|
| ToF | ASD | |||
| Trascription regulation | ATF3 | Activating transcription factor 3 | 35.8 | 13.4 |
| EGR3 | Early growth response 3 | 27.0 | 13.0 | |
| NR4A2 | Nuclear receptor subfamily 4, group A, member 2 | 20.7 | 18.2 | |
| NR4A3 | Nuclear receptor subfamily 4, group A, member 3 | 19.6 | 4.8 | |
| FOSB | FBJ murine osteosarcoma viral oncogene homolog B | 14.9 | 28.8 | |
| MAFF | v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F | 12.0 | 8.4 | |
| JUNB | Jun B proto-oncogene | 10.3 | 9.4 | |
| EGR2 | Early growth response 2 | 9.8 | 5.9 | |
| EGR1 | Early growth response 1 | 8.8 | 20.5 | |
| NR4A1 | Nuclear receptor subfamily 4, group A, member 1 | 6.5 | 5.3 | |
| NFKBIZ | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta | 6.3 | 2.2 | |
| MYC | v-myc avian myelocytomatosis viral oncogene homolog | 6.0 | 3.8 | |
| FOS | FBJ murine osteosarcoma viral oncogene homolog | 5.9 | 13.9 | |
| JUN | Jun proto-oncogene | 5.9 | 3.9 | |
| KLF4 | Kruppel-like factor 4 (gut) | 5.7 | 4.5 | |
| CSRNP1 | Cysteine-serine-rich nuclear protein 1 | 5.6 | 4.8 | |
| IER3 | Immediate early response 3 | 4.6 | 2.3 | |
| FOSL2 | FOS-like antigen 2 | 4.5 | 2.8 | |
| IER2 | Immediate early response | 2 4.0 | 5.0 | |
| HES1 | Hes family bHLH transcription factor 1 | 3.9 | 2.2 | |
| NFIL3 | Nuclear factor, interleukin 3 regulated | 3.9 | 2.4 | |
| KLF2 | Kruppel-like factor 2 | 2.3 | 2.2 | |
| Regulation of cell growth and apoptosis | MIR21/VMP1 | MicroRNA 21/vacuole membrane protein 1 | 11.4 | 5 |
| DUSP5 | Dual specificity phosphatase 5 | 5.4 | 3.1 | |
| GADD45B | Growth arrest and DNA-damage-inducible, beta | 5.2 | 2.6 | |
| CDKN1A | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 5.1 | 2.7 | |
| MIR22/MIR22HG | MicroRNA 22/MIR22 host gene | 4.5 | 2.8 | |
| MCL1 | Myeloid cell leukemia 1 | 4.4 | 2.5 | |
| MIR23A/MIR24-2 | MicroRNA 23a/24-2 | 4.3 | 3.3 | |
| BTG2 | BTG family, member 2 | 4.0 | 2.6 | |
| DUSP6 | Dual specificity phosphatase 6 | 3.7 | 3.2 | |
| CCNL1 | Cyclin L1 | 3.7 | 2 | |
| PPP1R15A/GADD34 | Protein phosphatase 1, regulatory subunit 15A/growth arrest and DNA-damage-inducible | 3.3 | 2.1 | |
| DUSP1 | Dual specificity phosphatase 1 | 2.2 | 2.1 | |
| Inflammatory response | SOCS3 | Suppressor of cytokine signaling 3 | 23.0 | 24.6 |
| PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 12.2 | 6.9 | |
| CCL2 | Chemokine (C–C motif) ligand 2 | 10.4 | 6.2 | |
| CXCL2 | Chemokine (C–X–C motif) ligand 2 | 9.3 | 11.7 | |
| RGS1 | Regulator of G-protein signaling 1 | 4.0 | 4.8 | |
| RGS2 | Regulator of G-protein signaling 2 | 3.6 | 2.0 | |
| C3 | Complement component 3 | 0.4 | 0.3 | |
| ITLN1 | Intelectin 1 (galactofuranose binding) | 0.05 | 0.1 | |
| Cell adhesion and matrix organization | ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif, 1 | 6.5 | 3.8 |
| CYR61 (CCN1) | Cysteine-rich, angiogenic inducer, 61 | 5.5 | 5.2 | |
| THBD | Thrombomodulin | 4.6 | 2.4 | |
| EFEMP1 | EGF containing fibulin-like extracellular matrix protein 1 | 0.4 | 0.4 | |
| COL3A1 | Collagen, type III, alpha 1 | 0.2 | 0.2 | |
| Antioxidant activity | MT1M | Metallothionein 1M | 14.3 | 5.9 |
| NCOA7 | Nuclear receptor coactivator 7 | 4.7 | 2.2 | |
| MT2A | Metallothionein 2A | 3.1 | 2.0 | |
Comparative analysis of gene expression in Pre-CPB and Post-CPB ToF and ASD samples was conducted as described in “Methods” section. A function, a gene symbol, a brief gene description, and fold change values are specified for each gene
Genes for each functional category are ordered according to decreasing fold changes of ToF genes
aFold change was calculated as the ratio between the mean expression value of Post-CPB and Pre-CPB samples for each gene. Fold change ≥ 2 or ≤ 0.5 are considered significant